Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.45 |
| ▸ | UMPS | P11172 | 3/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212380 | 0.87 | P2RY2 (0.47) | P2RY2UMPSP2RY6P2RY4SLC28A1 | |
| SCHEMBL3218065 | 0.87 | P2RY2 (0.45) | P2RY2UMPSP2RY6P2RY4SLC28A1 | |
| SCHEMBL3211527 | 0.85 | P2RY2 (0.43) | P2RY2UMPSP2RY6P2RY4SLC28A1 | |
| SCHEMBL3221053 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3221041 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13423829 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13455784 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3218829 | 0.83 | P2RY2 (0.46) | P2RY2UMPSP2RY6P2RY4SLC28A1 | |
| SCHEMBL12144307 | 0.83 | P2RY2 (0.58) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL3220723 | 0.83 | P2RY2 (0.58) | P2RY2UMPSP2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | P2RY2 1891/4885UMPS 17/4885P2RY6 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.